{"id":"bolus-dose-of-cefazolin","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Hypersensitivity reactions (rash, urticaria)"},{"rate":"1-2","effect":"Phlebitis at injection site"},{"rate":"1-2","effect":"Diarrhea"},{"rate":"0.5-1","effect":"Nausea/vomiting"},{"rate":"0.01-0.1","effect":"Anaphylaxis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cefazolin is a first-generation cephalosporin antibiotic that works by disrupting the formation of the bacterial cell wall. It binds to penicillin-binding proteins and prevents the cross-linking of peptidoglycan strands, which are essential for cell wall integrity. This leads to cell wall instability and bacterial cell death, making it bactericidal against susceptible gram-positive and some gram-negative organisms.","oneSentence":"Cefazolin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking cross-linking of peptidoglycan.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:39:17.975Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Surgical site infection prophylaxis"},{"name":"Bacterial infections caused by susceptible organisms (skin, soft tissue, respiratory, urinary tract, biliary, bone, and joint infections)"}]},"trialDetails":[{"nctId":"NCT07337135","phase":"NA","title":"Opioid-Free vs Opioid-Based Anesthesia in Bariatric Surgery","status":"COMPLETED","sponsor":"Hospital dos Lusíadas","startDate":"2023-10-02","conditions":"Morbid Obesity, Postoperative Pain, Opioid Free Anesthesia","enrollment":60},{"nctId":"NCT05655091","phase":"PHASE2","title":"Target Attainment of Continuous Infusion Flucloxacillin and Cefazolin Coupled With TDM vs. Standard of Care Treatment in Patients With Complicated S. Aureus Infection","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2023-10-26","conditions":"Complicated Staphylococcus Aureus (S. Aureus) Infections (CSAI)","enrollment":36},{"nctId":"NCT03190668","phase":"PHASE4","title":"Skeletal Muscle and Adipose Tissue Study","status":"COMPLETED","sponsor":"University of Florida","startDate":"2018-05-29","conditions":"Idiopathic Scoliosis","enrollment":12},{"nctId":"NCT04503252","phase":"","title":"Probability of Target Attainment With Standard Intermittent Bolus Administration of Cefazolin in Patients With Complicated Infections Caused by Staphylococcus Aureus","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2020-01-14","conditions":"Staphylococcus Aureus Infection","enrollment":50},{"nctId":"NCT02666365","phase":"PHASE4","title":"Continuous v Bolus Infusion of Cefazolin During Ventral Hernia Repair","status":"WITHDRAWN","sponsor":"Milton S. Hershey Medical Center","startDate":"2018-03","conditions":"Surgical Site Infections","enrollment":""},{"nctId":"NCT02433704","phase":"PHASE4","title":"Preoperative Antibiotic Dosing for Total Knee Arthroplasty","status":"WITHDRAWN","sponsor":"Duke University","startDate":"2015-05","conditions":"Acute Infection of Total Knee Replacement","enrollment":""},{"nctId":"NCT02058979","phase":"NA","title":"Pharmacokinetics of Bolus Versus Continuous Cefazolin Infusion in Patients Undergoing Major Surgery","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2014-11","conditions":"Plasma Concentration of Antibiotics","enrollment":20},{"nctId":"NCT02502877","phase":"NA","title":"Core Temperature Variations During Midazolam vs Propofol Sedation for Neuraxial Anesthesia","status":"COMPLETED","sponsor":"Hospital da Luz, Portugal","startDate":"2015-07","conditions":"Body Temperature Changes, Anesthesia","enrollment":27},{"nctId":"NCT01810354","phase":"NA","title":"PROPHYLACTIC ANTIBIOTICS PRIOR TO CESAREAN SECTION IN OBESE WOMEN","status":"COMPLETED","sponsor":"Women and Infants Hospital of Rhode Island","startDate":"2013-04","conditions":"Infection Prevention","enrollment":58}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Standard mode of prophylactic cefazolin administration"],"phase":"marketed","status":"active","brandName":"Bolus dose of Cefazolin","genericName":"Bolus dose of Cefazolin","companyName":"University of Florida","companyId":"university-of-florida","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cefazolin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking cross-linking of peptidoglycan. Used for Surgical site infection prophylaxis, Bacterial infections caused by susceptible organisms (skin, soft tissue, respiratory, urinary tract, biliary, bone, and joint infections).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}